21 November 2014 - Biodefence company PharmAthene (NYSE MKT:PIP) said on Thursday that it has met its obligations of a fixed price, indefinite delivery, indefinite quantity (IDIQ) contract for its anthrax anti-toxin, Valortim.

This agreement was awarded to PharmAthene in 2013 by the Biomedical Advanced Research and Development Authority (BARDA).

As part of the 2013 IDIQ agreement, PharmAthene was selected to provide a specified quantity of its Valortim anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.